Mia®, a deep learning artificial intelligence (AI) solution that works with radiologists to improve breast cancer detection, avoid unnecessary biopsies and ultimately improve the patient experience for all women is being launched in the UAE.
On the sidelines of Arab Health 2021, UK-based Kheiron Medical Technologies signed an agreement with Atlas Medical LLC, a medical device and pharma distributor focused on bringing state-of-the-art healthcare technology to the UAE. As part of the agreement, Atlas will bring Kheiron’s Mia solution to the UAE market. With patented AI technology developed on more than three million breast images, Mia (Mammography Intelligent Assessment) is designed to support breast radiologists in making the critical decision to recall women for further testing based on their mammography screening.
Kheiron Medical Technologies is an applied science company focused on supporting cancer diagnostics with machine learning that works with radiologists so that every patient has a better fighting chance.
Atlas Medical partners with leading medical device and technology manufacturers to bring high-value products and services to the UAE healthcare sector.
Mia is the first solution of its kind to receive the CE (European regulatory clearance) mark for use as an AI-enabled independent reader for the detection of breast cancer. Through rigorous clinical studies and testing, Mia has learnt to read mammograms to the same level of detail as a consulting radiologist.
In double-reading mammography workflows where scans are reviewed by two radiologists, Mia can be deployed independently alongside a single human reader. This delivers the quality improvements needed to ensure the sustainability of breast screening services and frees up clinicians to spend more time with patients.Mia can also be deployed as a concurrent reader or in double reader triage.
Her Majesty’s Trade Commissioner for the Middle East, Simon Penney, added: “I am delighted that Kheiron Medical Technologies is bringing their breakthrough AI platform for breast screening, Mia, to the Gulf region, and that the UK’s Department for International Trade played a role in making this happen. Kheiron’s technology brings pioneering artificial intelligence to the frontline, freeing up clinicians’ time and helping to save lives.”
Speaking at a signing ceremony between Kheiron and Atlas Medical held at Arab Health in Dubai, Alex Hamlow, Kheiron’sChief Commercial Officer, said; “Our mission at Kheiron is to support breast screening professionals in the fight against breast cancer with proven and effective AI-enabled tools. We’re excited that Mia is the first AI independent reader solution available for use within the breast screening community in the United Arab Emirates.Based on its performance in the UK and Europe, Mia represents a major breakthrough in helping radiologists to dramatically improve breast cancer detection and patient outcomes.
“According to the WHO’s International Agency for Research on Cancer, breast cancer was the most prevalent of all cancers detected in the UAE in 2020, accounting for 38.8% of all new cancer cases detected in women. I’m excited that Mia can help both radiologists and the women they care for,” Mr Hamlow continued.
“We are looking forward to bringing the Mia solution to the breast screening community throughout the United Arab Emirates,” comments V. Kalyanasundaram, General Manager for Atlas Medical in Dubai and the Northern Emirates.
He also added, “It has tremendous potential to transform breast screening for radiologists and for women. By improving radiologist productivity and empowering breast screening professionals to detect potential malignancies more accurately and quickly, Mia ultimately will help save more lives in the fight against breast cancer.”
Mia’s effectiveness has been proven in one of the most ambitious clinical studies in radiology AI to date and tested across multiple demographics and mammography devices. It was one of the recipients of the UK Government’s first AI in Health and Care Awards through which Mia is undergoing multiple deployments and clinical studies across 15 sites in the UK as a benchmark for how to integrate new, cutting edge technologies into the NHS safely and effectively. Kheiron and AI Advance are currently working with an Australian breast-screening provider to establish the protocols for a forthcoming clinical trial, details of which will soon be announced.
Mia will be available to the UAE, Qatar and Oman markets pending local requirements.